Chimeric antigen receptor-T-cellebehandling

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Chimeric antigen receptor-T-cellebehandling. / Müller, Klaus; Ifversen, Marianne; Kielsen, Katrine; Petersen, Søren Lykke; Met, Özcan; Svane, Inge Marie.

I: Ugeskrift for Laeger, Bind 181, Nr. 20A, V05190309, 2019.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Müller, K, Ifversen, M, Kielsen, K, Petersen, SL, Met, Ö & Svane, IM 2019, 'Chimeric antigen receptor-T-cellebehandling', Ugeskrift for Laeger, bind 181, nr. 20A, V05190309. <https://ugeskriftet.dk/videnskab/chimeric-antigen-receptor-t-cellebehandling>

APA

Müller, K., Ifversen, M., Kielsen, K., Petersen, S. L., Met, Ö., & Svane, I. M. (2019). Chimeric antigen receptor-T-cellebehandling. Ugeskrift for Laeger, 181(20A), [V05190309]. https://ugeskriftet.dk/videnskab/chimeric-antigen-receptor-t-cellebehandling

Vancouver

Müller K, Ifversen M, Kielsen K, Petersen SL, Met Ö, Svane IM. Chimeric antigen receptor-T-cellebehandling. Ugeskrift for Laeger. 2019;181(20A). V05190309.

Author

Müller, Klaus ; Ifversen, Marianne ; Kielsen, Katrine ; Petersen, Søren Lykke ; Met, Özcan ; Svane, Inge Marie. / Chimeric antigen receptor-T-cellebehandling. I: Ugeskrift for Laeger. 2019 ; Bind 181, Nr. 20A.

Bibtex

@article{b10611b34924406e8e59ebcb6276abc9,

title = "Chimeric antigen receptor-T-cellebehandling",

abstract = "Although treatment of haematological cancer has improved significantly during the latest decades, the prognosis is poor in case of relapse or refractory disease. This review describes the chimeric antigen receptor (CAR) T-cell therapy, which has emerged as a new promising treatment principle, in which the patient's own T-cells are genetically modified to recognise cancer cells. The possible side effects are usually only transient. A commercial CD19 CAR T-cell product has recently been approved as treatment for acute lympho-blastic leukaemia in children and young adults in Denmark, and a non-commercial CAR T-cell production is being established.",

author = "Klaus M{\"u}ller and Marianne Ifversen and Katrine Kielsen and Petersen, {S{\o}ren Lykke} and {\"O}zcan Met and Svane, {Inge Marie}",

year = "2019",

language = "Dansk",

volume = "181",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "20A",

}

RIS

TY - JOUR

T1 - Chimeric antigen receptor-T-cellebehandling

AU - Müller, Klaus

AU - Ifversen, Marianne

AU - Kielsen, Katrine

AU - Petersen, Søren Lykke

AU - Met, Özcan

AU - Svane, Inge Marie

PY - 2019

Y1 - 2019

N2 - Although treatment of haematological cancer has improved significantly during the latest decades, the prognosis is poor in case of relapse or refractory disease. This review describes the chimeric antigen receptor (CAR) T-cell therapy, which has emerged as a new promising treatment principle, in which the patient's own T-cells are genetically modified to recognise cancer cells. The possible side effects are usually only transient. A commercial CD19 CAR T-cell product has recently been approved as treatment for acute lympho-blastic leukaemia in children and young adults in Denmark, and a non-commercial CAR T-cell production is being established.

AB - Although treatment of haematological cancer has improved significantly during the latest decades, the prognosis is poor in case of relapse or refractory disease. This review describes the chimeric antigen receptor (CAR) T-cell therapy, which has emerged as a new promising treatment principle, in which the patient's own T-cells are genetically modified to recognise cancer cells. The possible side effects are usually only transient. A commercial CD19 CAR T-cell product has recently been approved as treatment for acute lympho-blastic leukaemia in children and young adults in Denmark, and a non-commercial CAR T-cell production is being established.

M3 - Tidsskriftartikel

C2 - 31610841

VL - 181

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

SN - 0041-5782

IS - 20A

M1 - V05190309

ER -

ID: 238526118